Lineage Cell Therapeutics (LCTX) Cash from Financing Activities (2010 - 2026)

Lineage Cell Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 10.25% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $27.5 million, a 2.18% increase from a year earlier, with the FY2025 full-year figure at $27.0 million, down 24.84% from the prior year.
• Cash from Financing Activities slipped to $5.6 million in Q1 2026 per LCTX's latest filing, from $20.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $21.7 million in Q4 2024 and bottomed at -$307000.0 in Q2 2025.
• The 5-year median for Cash from Financing Activities is $807000.0 (2023), against an average of $4.5 million.
• Across the five-year window, Cash from Financing Activities soared 1402000.0% in 2024 and slumped 392.38% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $122000.0 in 2022, then plunged by 110.66% to -$13000.0 in 2023, then soared by 167284.62% to $21.7 million in 2024, then slipped by 6.23% to $20.4 million in 2025, then slumped by 72.71% to $5.6 million in 2026.
• Per Business Quant, the three latest LCTX Cash from Financing Activities figures stand at $5.6 million (Q1 2026), $20.4 million (Q4 2025), and $1.8 million (Q3 2025).